TheEdgeResearch
Home / Stocks / ADMA

ADMA Biologics, Inc. (ADMA)

NASDAQ Healthcare Biotechnology
$9.08 ▼ -2.05%
Market Cap
$2.10B
Sector
Healthcare
Industry
Biotechnology
Beta
0.73
52-Wk Range
7.21-20.458
CEO
Adam S. Grossman
Country
US
Currency
USD

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment …

Open full interactive analysis & DCF →